-
1
-
-
65449136656
-
Diagnosis, management, and treatment of hepatitis C: An update
-
Ghany MG, Strader DB, Thomas DL, Seef LB. Diagnosis, management, and treatment of hepatitis C: an update. AASLD practice guidelines. Hepatology 2009; 49: 1335-74.
-
(2009)
AASLD practice guidelines. Hepatology
, vol.49
, pp. 1335-1374
-
-
Ghany, M.G.1
Strader, D.B.2
Thomas, D.L.3
Seef, L.B.4
-
2
-
-
0033998786
-
The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States
-
Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777-82.
-
(2000)
Hepatology
, vol.31
, pp. 777-782
-
-
Armstrong, G.L.1
Alter, M.J.2
McQuillan, G.M.3
Margolis, H.S.4
-
3
-
-
0036828784
-
The burden of hepatitis C in the United States
-
Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36: S30-4.
-
(2002)
Hepatology
, vol.36
-
-
Kim, W.R.1
-
4
-
-
0036207348
-
The association between hepatitis C infection and survival after orthotopic liver transplantation
-
Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-96.
-
(2002)
Gastroenterology
, vol.122
, pp. 889-896
-
-
Forman, L.M.1
Lewis, J.D.2
Berlin, J.A.3
Feldman, H.I.4
Lucey, M.R.5
-
5
-
-
0029914375
-
Long-term outcome of hepatitis C infection after liver transplantation
-
Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, Maertens G, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-20.
-
(1996)
N Engl J Med
, vol.334
, pp. 815-820
-
-
Gane, E.J.1
Portmann, B.C.2
Naoumov, N.V.3
Smith, H.M.4
Underhill, J.A.5
Donaldson, P.T.6
Maertens, G.7
-
6
-
-
18444415726
-
Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients
-
Berenguer M, Prieto M, San JF, Rayon JM, Martinez F, Carrasco D, Moya A, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 02-10.
-
(2002)
Hepatology
, vol.36
, pp. 2-10
-
-
Berenguer, M.1
Prieto, M.2
San, J.F.3
Rayon, J.M.4
Martinez, F.5
Carrasco, D.6
Moya, A.7
-
7
-
-
0026734480
-
Reinfection of liver graft by hepatitis C virus after liver transplantation
-
Feray C, Samuel D, Thiers V, Gigou M, Pichon F, Bismuth A, Reynes M, et al. Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest 1992; 89: 1361-5.
-
(1992)
J Clin Invest
, vol.89
, pp. 1361-1365
-
-
Feray, C.1
Samuel, D.2
Thiers, V.3
Gigou, M.4
Pichon, F.5
Bismuth, A.6
Reynes, M.7
-
8
-
-
0036793302
-
Natural history of recurrent hepatitis C
-
Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002; 8: S14-8.
-
(2002)
Liver Transpl
, vol.8
-
-
Berenguer, M.1
-
9
-
-
33847007641
-
Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy)
-
Bahra M, Neumann UP, Jacob D, Langrehr JM, Berg T, Neuhaus R, Neuhaus P. Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy). Transplantation 2007; 83: 351-3.
-
(2007)
Transplantation
, vol.83
, pp. 351-353
-
-
Bahra, M.1
Neumann, U.P.2
Jacob, D.3
Langrehr, J.M.4
Berg, T.5
Neuhaus, R.6
Neuhaus, P.7
-
10
-
-
46349089961
-
Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin
-
Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-87.
-
(2008)
J Hepatol
, vol.49
, pp. 274-287
-
-
Berenguer, M.1
-
11
-
-
52149121573
-
Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: Systematic review and meta-analysis of prospective controlled studies
-
Xirouchakis E, Triantos C, Manousou P, Sigalas A, Calvaruso V, Corbani A, Leandro G, et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat 2008; 15: 699-709.
-
(2008)
J Viral Hepat
, vol.15
, pp. 699-709
-
-
Xirouchakis, E.1
Triantos, C.2
Manousou, P.3
Sigalas, A.4
Calvaruso, V.5
Corbani, A.6
Leandro, G.7
-
12
-
-
33745343818
-
Interferon based combination anti-viral therapy for hepatitis C virus after liver transplantation: A review and quantitative analysis
-
Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6: 1586-99.
-
(2006)
Am J Transplant
, vol.6
, pp. 1586-1599
-
-
Wang, C.S.1
Ko, H.H.2
Yoshida, E.M.3
Marra, C.A.4
Richardson, K.5
-
13
-
-
33846589289
-
Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation
-
Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo CG, Lampasi F, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459-65.
-
(2007)
J Hepatol
, vol.46
, pp. 459-465
-
-
Picciotto, F.P.1
Tritto, G.2
Lanza, A.G.3
Addario, L.4
De Luca, M.5
Di Costanzo, C.G.6
Lampasi, F.7
-
14
-
-
39649100163
-
Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation
-
Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679-87.
-
(2008)
Am J Transplant
, vol.8
, pp. 679-687
-
-
Berenguer, M.1
Palau, A.2
Aguilera, V.3
Rayon, J.M.4
Juan, F.S.5
Prieto, M.6
-
15
-
-
84879551010
-
Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation
-
Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, Yataco ML, et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013; 19: 690-700.
-
(2013)
Liver Transpl
, vol.19
, pp. 690-700
-
-
Pungpapong, S.1
Aqel, B.A.2
Koning, L.3
Murphy, J.L.4
Henry, T.M.5
Ryland, K.L.6
Yataco, M.L.7
-
16
-
-
84890558343
-
Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience
-
Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014; 60: 78-86.
-
(2014)
J Hepatol
, vol.60
, pp. 78-86
-
-
Coilly, A.1
Roche, B.2
Dumortier, J.3
Leroy, V.4
Botta-Fridlund, D.5
Radenne, S.6
Pageaux, G.P.7
-
17
-
-
84870862182
-
Telaprevir based triple therapy in liver transplant patients with hepatitis C virus: A 12-week pilot study providing safety and efficacy data
-
Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP, et al. Telaprevir based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl 2012; 18: 1464-70.
-
(2012)
Liver Transpl
, vol.18
, pp. 1464-1470
-
-
Werner, C.R.1
Egetemeyr, D.P.2
Lauer, U.M.3
Nadalin, S.4
Königsrainer, A.5
Malek, N.P.6
Berg, C.P.7
-
18
-
-
84868208266
-
Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers
-
Hulskotte E, Gupta S, Xuan F, van Zutven M, O'Mara E, Feng HP, Wagner J, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012; 56: 1622-30.
-
(2012)
Hepatology
, vol.56
, pp. 1622-1630
-
-
Hulskotte, E.1
Gupta, S.2
Xuan, F.3
van Zutven, M.4
O'Mara, E.5
Feng, H.P.6
Wagner, J.7
-
19
-
-
0029778988
-
An algorithm for the grading of activity in chronic hepatitis C
-
The METAVIR Cooperative Study Group
-
Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
-
(1996)
Hepatology
, vol.24
, pp. 289-293
-
-
Bedossa, P.1
Poynard, T.2
-
20
-
-
80053339008
-
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
-
Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology 2011 54: 433-44
-
(2011)
Hepatology
, Issue.54
, pp. 433-444
-
-
Ghany, M.G.1
Nelson, D.R.2
Strader, D.B.3
Thomas, D.L.4
Seeff, L.B.5
-
21
-
-
84878746682
-
First Successful Treatment of Post-Liver Transplant Hepatitis C Fibrosing Cholestatic Hepatitis with Boceprevir, Peginterferon and Ribavirin in a Pre-Transplant Null Responder
-
Al Nahdi N, Ford JA, Greanya E, Harrigan JA, Tse I, Steinbrecher UP, Erb SR, et al. First Successful Treatment of Post-Liver Transplant Hepatitis C Fibrosing Cholestatic Hepatitis with Boceprevir, Peginterferon and Ribavirin in a Pre-Transplant Null Responder. Ann Hepatol 2013; 12: 156-60.
-
(2013)
Ann Hepatol
, vol.12
, pp. 156-160
-
-
Al Nahdi, N.1
Ford, J.A.2
Greanya, E.3
Harrigan, J.A.4
Tse, I.5
Steinbrecher, U.P.6
Erb, S.R.7
-
23
-
-
58249086156
-
Hepatitis C virus therapy in liver transplant recipients, response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis
-
Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, Saliba F, et al. Hepatitis C virus therapy in liver transplant recipients, response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008;14: 1766-77.
-
(2008)
Liver Transpl
, vol.14
, pp. 1766-1777
-
-
Roche, B.1
Sebagh, M.2
Canfora, M.L.3
Antonini, T.4
Roque-Afonso, A.M.5
Delvart, V.6
Saliba, F.7
-
24
-
-
33846256585
-
Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection post transplantation
-
Bizollon T, Pradat P, Mabrut JY, Radenne S, Ducerf C, Baulieux J, Souquet JC, et al. Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection post transplantation. Am J Transplant 2007; 7: 448-53.
-
(2007)
Am J Transplant
, vol.7
, pp. 448-453
-
-
Bizollon, T.1
Pradat, P.2
Mabrut, J.Y.3
Radenne, S.4
Ducerf, C.5
Baulieux, J.6
Souquet, J.C.7
-
25
-
-
33745997054
-
Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C
-
Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M, Rayon JM, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006; 12: 1067-76
-
(2006)
Liver Transpl
, vol.12
, pp. 1067-1076
-
-
Berenguer, M.1
Palau, A.2
Fernandez, A.3
Benlloch, S.4
Aguilera, V.5
Prieto, M.6
Rayon, J.M.7
-
26
-
-
84892372669
-
End of Treatment Response after Protease-Inhibitor (PI)-based Therapy for Hepatitis C Recurrence after Liver Transplantation: A Multicentric European Experience (Abstract #1422)
-
doi:10.1016/S0168-8278(13)61420-8
-
Coilly A, Dumortier J, Botta-Fridlund D, Latournierie M, Leroy V, Pageaux GP, Giostra CE, et al. End of Treatment Response after Protease-Inhibitor (PI)-based Therapy for Hepatitis C Recurrence after Liver Transplantation: A Multicentric European Experience (Abstract #1422). J Hepatol 58: S572. doi:10.1016/S0168-8278(13)61420-8.
-
J Hepatol
, vol.58
-
-
Coilly, A.1
Dumortier, J.2
Botta-Fridlund, D.3
Latournierie, M.4
Leroy, V.5
Pageaux, G.P.6
Giostra, C.E.7
-
27
-
-
84855244456
-
Boceprevir and telaprevir for the treatment of chronic hepatitis C, safety management in clinical practice
-
Hezode C. Boceprevir and telaprevir for the treatment of chronic hepatitis C, safety management in clinical practice. Liver Int 2012; 32: 32-8.
-
(2012)
Liver Int
, vol.32
, pp. 32-38
-
-
Hezode, C.1
-
28
-
-
84906303033
-
A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy
-
May 5. pii: S0168-8278(14)00300-6. doi:10.1016/j.jhep.2014.04. 037. [Epub ahead of print]
-
Burton JR, O'Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, Levitsky J, et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol 2014 May 5. pii: S0168-8278(14)00300-6. doi:10.1016/j.jhep.2014.04. 037. [Epub ahead of print]
-
(2014)
J Hepatol
-
-
Burton, J.R.1
O'Leary, J.G.2
Verna, E.C.3
Saxena, V.4
Dodge, J.L.5
Stravitz, R.T.6
Levitsky, J.7
-
29
-
-
84874500142
-
Anemia during treatment with peginterferon alfa-2b/ribavirin and boceprevir: Analysis from the SPRINT-2 trial
-
Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Reddy KR, Harrison SA, Afdhal NH, et al. Anemia during treatment with peginterferon alfa-2b/ribavirin and boceprevir: analysis from the SPRINT-2 trial. Hepatology 2013; 57: 974-84.
-
(2013)
Hepatology
, vol.57
, pp. 974-984
-
-
Sulkowski, M.S.1
Poordad, F.2
Manns, M.P.3
Bronowicki, J.P.4
Reddy, K.R.5
Harrison, S.A.6
Afdhal, N.H.7
-
30
-
-
84855263813
-
Telaprevir, an oral protease inhibitor for hepatitis C virus infection
-
Kim JJ, Culley CM, Mohammad RA. Telaprevir, an oral protease inhibitor for hepatitis C virus infection. Am J Health Syst Pharm 2012; 69: 19-33.
-
(2012)
Am J Health Syst Pharm
, vol.69
, pp. 19-33
-
-
Kim, J.J.1
Culley, C.M.2
Mohammad, R.A.3
-
31
-
-
70349533037
-
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
-
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 7: 1105-9.
-
(2009)
Nat Genet
, vol.7
, pp. 1105-1109
-
-
Tanaka, Y.1
Nishida, N.2
Sugiyama, M.3
Kurosaki, M.4
Matsuura, K.5
Sakamoto, N.6
Nakagawa, M.7
|